Ravgen’s core technology is based on its ability to increase the percentage of fetal DNA that is found in the mother’s blood. Through its research with free floating fetal DNA, the company has developed and patented a variety of noninvasive prenatal tests that simply require a safe blood draw from the mother. Currently, the focus for Ravgen’s core technology is on testing for single gene disorders, such as cystic fibrosis, sickle cell anemia, and the Jewish panel, as well as prenatal paternity testing.